ATE526958T1 - Acetyl-l-carnitin für die vorbeugung und/oder behandlung von peripheren neuropathien hervorgerufen durch thalidomid - Google Patents

Acetyl-l-carnitin für die vorbeugung und/oder behandlung von peripheren neuropathien hervorgerufen durch thalidomid

Info

Publication number
ATE526958T1
ATE526958T1 AT03775788T AT03775788T ATE526958T1 AT E526958 T1 ATE526958 T1 AT E526958T1 AT 03775788 T AT03775788 T AT 03775788T AT 03775788 T AT03775788 T AT 03775788T AT E526958 T1 ATE526958 T1 AT E526958T1
Authority
AT
Austria
Prior art keywords
thalidomide
carnitine
acetyl
prevention
treatment
Prior art date
Application number
AT03775788T
Other languages
German (de)
English (en)
Inventor
C Cavazza
C Pisano
L Vesci
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE526958T1 publication Critical patent/ATE526958T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03775788T 2002-11-13 2003-10-23 Acetyl-l-carnitin für die vorbeugung und/oder behandlung von peripheren neuropathien hervorgerufen durch thalidomid ATE526958T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/292,823 US20030199535A1 (en) 1998-07-30 2002-11-13 Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
PCT/IT2003/000656 WO2004043454A1 (en) 2002-11-13 2003-10-23 Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents

Publications (1)

Publication Number Publication Date
ATE526958T1 true ATE526958T1 (de) 2011-10-15

Family

ID=32312146

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03775788T ATE526958T1 (de) 2002-11-13 2003-10-23 Acetyl-l-carnitin für die vorbeugung und/oder behandlung von peripheren neuropathien hervorgerufen durch thalidomid

Country Status (19)

Country Link
US (2) US20030199535A1 (enExample)
EP (1) EP1562577B1 (enExample)
JP (1) JP2006508958A (enExample)
KR (1) KR20050075012A (enExample)
CN (1) CN1708297A (enExample)
AR (1) AR041947A1 (enExample)
AT (1) ATE526958T1 (enExample)
AU (2) AU2003283807B2 (enExample)
BR (1) BR0316131A (enExample)
CA (1) CA2505937C (enExample)
CY (1) CY1112399T1 (enExample)
DK (1) DK1562577T3 (enExample)
ES (1) ES2374503T3 (enExample)
MX (1) MXPA05004752A (enExample)
PL (1) PL379244A1 (enExample)
PT (1) PT1562577E (enExample)
SI (1) SI1562577T1 (enExample)
TW (1) TWI362260B (enExample)
WO (1) WO2004043454A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018767A2 (en) * 2001-08-27 2003-03-06 Advanced Cell Technology, Inc. Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (en) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ITMI20070817A1 (it) * 2007-04-19 2008-10-20 Farmacetika Ltd Composizione farmaceutica comprendente l-carnitina ed un agente antagonista dei recettori adenosinici di membrana, loro derivati e/o sali farmaceuticamente accettabili, e uso degli stessi nella preparazione di farmaci con effetto non tossico di inibi
WO2008136374A1 (ja) * 2007-04-26 2008-11-13 Nippon Shinyaku Co., Ltd. 抗癌剤投与に伴う末梢神経障害抑制用医薬組成物
EP2191836B1 (en) * 2007-08-31 2012-05-23 Kyushu University, National University Corporation Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
MX2010004859A (es) * 2007-10-30 2010-06-21 Trophos Nueva composicion para tratar los efectos secundarios del tratamiento anticanceroso.
US20120208883A1 (en) * 2008-12-01 2012-08-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A Treatment of oncological diseases
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
ITPZ20130005A1 (it) * 2013-07-05 2015-01-06 Teodosio Antonio Ferrara Metabolismo energetico e omeostasi
JP7075937B2 (ja) 2016-11-09 2022-05-26 キアゲン サイエンシーズ, エルエルシー Sequencing-By-Synthesis法におけるイメージング試薬としての光防護性混合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713370A (en) * 1972-11-06 1987-12-15 Felice Stephen L De Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats
US4599352A (en) * 1984-03-01 1986-07-08 The United States Of America As Represented By The Department Of Health And Human Services Antineoplastic platinum (IV) complexes and compositions
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
JP4703851B2 (ja) * 1998-07-30 2011-06-15 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ L−カルニチンおよびそのアルカノイル誘導体の、抗癌作用を有する医薬品の製造のための使用

Also Published As

Publication number Publication date
WO2004043454A1 (en) 2004-05-27
MXPA05004752A (es) 2005-08-02
ES2374503T3 (es) 2012-02-17
CA2505937C (en) 2011-07-26
SI1562577T1 (sl) 2012-01-31
US20030199535A1 (en) 2003-10-23
CA2505937A1 (en) 2004-05-27
PT1562577E (pt) 2012-01-12
AU2009201384A1 (en) 2009-05-07
DK1562577T3 (da) 2012-01-23
JP2006508958A (ja) 2006-03-16
AU2003283807A1 (en) 2004-06-03
AU2003283807B2 (en) 2009-12-03
AR041947A1 (es) 2005-06-01
CN1708297A (zh) 2005-12-14
EP1562577B1 (en) 2011-10-05
US20060183798A1 (en) 2006-08-17
KR20050075012A (ko) 2005-07-19
EP1562577A1 (en) 2005-08-17
BR0316131A (pt) 2005-09-27
CY1112399T1 (el) 2015-12-09
TW200410683A (en) 2004-07-01
TWI362260B (en) 2012-04-21
PL379244A1 (pl) 2006-08-07

Similar Documents

Publication Publication Date Title
EP1759710A4 (en) PREVENTIVE MEDICINE OR REMEDY FOR ARTHRITIS
DE60324777D1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
DE60221627D1 (de) Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
DE60239218D1 (de) Synergistische zusammensetzungen für die behandlung von saatgut
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
EP1513403A4 (en) USE OF CARDIOTONIC GLUCOSIDES FOR THE TREATMENT OF MUCOVICIDOSIS AND OTHER IL-8 DEPENDENT DISORDERS
DE602005011279D1 (de) Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
DE60228713D1 (de) Zusammensetzungen für die behandlung von haaren und/oder kopfhaut
EP1622633A4 (en) Treatment of t-cell mediated diseases
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
ATE526958T1 (de) Acetyl-l-carnitin für die vorbeugung und/oder behandlung von peripheren neuropathien hervorgerufen durch thalidomid
DE60327074D1 (de) Fluorobenzamide zur behandlung von alzheimer oder seniler dementia
ATE417616T1 (de) Behandlung von mukositis
EP1550462A4 (en) REMEDY OR PREVENTIVE AGENT AGAINST KIDNEY DISEASE AND METHOD OF DIAGNOSING KIDNEY DISEASE
ATE369130T1 (de) Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
ATE361745T1 (de) Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
EP1905452A4 (en) AGENT FOR THE PREVENTION OR TREATMENT OF GLAUCOMA
ATE407671T1 (de) Verwendung von sulfonamid-derivate zur herstellung eines medikaments für die vorbeugung oder behandlung von essstörungen
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
ATE429222T1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
DE502004011696D1 (de) Behandlung bakterieller erkrankungen der atmungsorgane durch lokale applikation von fluorchinolonen
ATE429221T1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
ATE457725T1 (de) Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1562577

Country of ref document: EP